Summary Modern tools for enzyme discovery combined with the development of increasingly reliable strategies for protein engineering have greatly expanded the range of enzymes with suitable properties for practical applications. This situation presents enormous opportunities for the design of sustainable biocatalytic strategies for the production of high-value chemicals. Here, we highlight recent contributions from our laboratory concerning -transaminases and monoamine oxidases, two enzyme classes that have been exploited for the industrial scale production of active pharmaceutical ingredients or key chiral intermediates. Firstly, we describe the development of novel 'smart' amine donors which overcome inherent challenges associated with controlling the equilibrium position of -TA catalyzed processes. Subsequently, we demonstrate how engineered variants of monoamine oxidase developed in our laboratory have been applied as biocatalysts for the synthesis of a diverse range of active pharmaceutical ingredients and alkaloid natural products. Through these illustrative examples, we hope to promote the wider application of enzymes within the synthetic community.
Introduction
In recent years, biocatalysis has emerged as an attractive and competitive technology for the production of optically pure chiral amines and amino acids (Höhne and Bornscheuer, 2009) . Several enzyme classes have now been exploited as biocatalysts in industrial scale manufacturing processes, including -transaminases (Savile et al., 2010) , monoamine oxidases (Li et al., 2012) and ammonia lyases (de Lange et al., 2011) . Particularly significant recent examples include the production of a key synthetic intermediate for Merck's hepatitis C drug boceprevir using a heavily engineered MAO-N variant (Li et al., 2012) , and the application of an evolved (R)-selective -TA for the synthesis of the antidiabetic compound sitagliptin (Savile et al., 2010) . In addition to these more 'established' enzyme classes, 'emerging' enzyme families such as imine reductases (Hussain et al., 2015) and amine dehydrogenases (Abrahamson et al., 2012) are likely to find synthetic applications in the coming years. Furthermore, the potential to exploit these enzymes in biocatalytic cascade processes is now being realized, providing new opportunities to replace multi-step transformations with more efficient single-step processes. A recent high-profile example from our laboratory involves a 'hydrogen borrowing' biocatalytic cascade for the direct conversion of alcohols to amines (Mutti et al., 2015) . In this perspective, we wish to highlight a selection of recent developments from our laboratory involving -TAs and MAOs, enzyme classes with broad synthetic potential that have impacted on the chemical industry.
Xylylenediamine: a smart amine donor for transaminase catalyzed processes
The asymmetric reductive amination of ketones with ammonia has been identified as a highly desirable transformation for use in the pharmaceutical industry (Constable et al., 2007) . This fundamental transformation remains a considerable challenge in organic synthesis which typically requires a multi-step approach (Nugent et al., 2006) , impacting upon the overall efficiency of this process. In recent years, biocatalytic strategies have been developed to overcome these existing limitations (Koszelewski et al., 2010; Mathew and Yun, 2012) . -TAs are a family of pyridoxal-5 -phosphate (PLP)-dependent enzymes that utilize a sacrificial amine donor to mediate the reversible conversion of prochiral ketones to the corresponding chiral primary amines in a single operation. The broad substrate scope, high stability and high levels of stereo control associated with engineered -TA variants makes them ideal biocatalysts for use in synthetic transformations. Despite this enormous potential, fundamental challenges associated with controlling unfavourable equilibrium positions are hindering the widespread application of this methodology (Shin and Kim, 1999) . With few exceptions, existing strategies rely on the use of amine donors in large excess combined with in situ removal of the carbonyl by-products to achieve high conversions to the desired amine products. The most widely employed strategy uses alanine as the amine donor and relies on the use of additional enzymes for the in situ removal of the pyruvate by-product (Fig. 1A) (Höhne et al., 2008; Koszelewski et al., 2008; Truppo et al., 2009; Shin and Kim, 1999) . Unfortunately, the application of this approach for scalable amine synthesis is limited by the complexity of these systems and the high costs associated with their use. Currently, the favoured strategy for large scale transformations involves the use of a large excess of isopropylamine as an amine donor combined with the selective in situ evaporation of the acetone by-product, an approach recently exploited in second generation biocatalytic process for the synthesis of the anti-diabetic API sitagliptin (Fig. 1B) (Savile et al., 2010) . Using this system, good to excellent conversions of selected substrates have been achieved (Han et al., 2015) . However, for those substrates which suffer from unfavourable equilibrium positions, to obtain the low concentrations of acetone required to achieve high conversions represents a significant technical challenge (Tufvesson et al., 2011) .
In light of these existing challenges, there remains a clear demand for the development of broadly applicable and operationally simple methods of conducting -TA mediated processes. In this regard, we recently identified orthoxylylenediamine dihydrochloride (1) as a highly effective amine donor for these biocatalytic transformations (Green et al., 2014) . The use of stoichiometric quantities of this reagent results in quantitative conversions to the desired 
Figure 2 Biocatalytic conversion of ketones to chiral amines using diamine 1 as the donor, leading to the formation of coloured polyisoindole byproducts. chiral amine products in the absence of by-product removal systems. The success of this system can be attributed to the spontaneous aromatization of the cyclic imine by-product (2) to the more stable isoindole (3), effectively removing this component from the system (Fig. 2) . Significantly, this electron rich isoindole by-product is spontaneously converted to intensely coloured polymeric derivatives via oxidative processes (Bonnett et al., 1973) , providing an operationally simple and sensitive method to detect desired transaminase activity. These coloured structures can be easily detected in liquid phase transformations or directly in Escherichia coli colonies expressing transaminase genes. Such high-throughput assays are extremely desirable for the identification of new transaminases, optimization of enzyme properties through directed evolution or for rapid substrate profiling of -TA variants.
Using ATA113, an (S)-selective -TA commercialized by Codexis ® , benzaldehyde (4) and a panel of prochiral ketones (5-11) were efficiently converted to the corresponding primary amines with excellent conversions and high optical purity using <1.5 equiv. of diamine (1) ( Table 1) (Green et al., 2014) . Amination of dicarbonyl (10) proceeded in a regioand stereoselective manner at the methyl ketone moiety. This was followed by spontaneous dehydrative cyclization to form the corresponding pyrroline as the sole product as previously reported (O'Reilly et al., 2014a; O'Reilly and Turner, 2015) . The biocatalytic amination of 1-indanone (11) represents a considerable challenge due to a highly unfavourable equilibrium position (Shin and Kim, 1999) . Impressive conversions of 54 and 73% to (S)-1-aminoindane were achieved using 1.0 and 1.5 equiv. of diamine (1), respectively. In contrast, a modest 21% conversion was obtained using 10 equiv. L-alanine and the LDH/GDH by-product removal system. In the absence of pyruvate removal, no conversion was detected using up to 100 equiv. of alanine. This direct comparison demonstrates the remarkable efficiency of 1 as an amine donor in transaminase mediated processes. Diamine (1) has been shown to be a compatible amine donor for a panel of twelve (six (S)-selective and six (R)-selective) commercially available -TA biocatalysts supplied by Codexis ® , although reduced conversions are typically observed with the (R)-selective enzymes compared with the (S)-selective counterparts. Combined, these biocatalysts display an extremely broad substrate scope for structurally diverse ketones. Since the transaminase mechanism proceeds via two half equations, the substrate scope of a -TA variant is unlikely to be influenced by the choice of amine donor.
In summary, the use of ortho-xylylenediamine as an amine donor provides an efficient and operationally simple method for the biocatalytic conversion of prochiral ketones to chiral primary amines. This technology compares favourably with existing chemical methods to achieve this fundamental transformation which typically require a multi-step strategy. The generation of intensely coloured by-products is currently being exploited in our laboratory as a high-throughput screening platform for enzyme engineering and substrate profiling. We are also actively seeking to identify alternative 'smart' amine donors which retain 
Synthetic applications of engineered MAO-N variants
Monomaine oxidase from Aspergillus niger is a flavin dependant enzyme that mediates the conversion of amines to the corresponding imines utilizing molecular oxygen as the stoichiometric oxidant. Wild-type MAO-N displays a rather narrow substrate tolerance, with appreciable levels of activity limited to simple, non-chiral primary amines (e.g., butylamine, benzylamine). Over a number of years, we have adopted a substrate walking approach to engineer variants that are able to tolerate chiral primary, secondary and tertiary amines with broad structural features (Alexeeva et al., 2002; Carr et al., 2003; Dunsmore et al., 2006; Ghislieri et al., 2013a) . The key to success of this evolutionary endeavour was the development of a substrate independent high-throughput colony-based assay based on the detection of the H 2 O 2 by-product (Alexeeva et al., 2002) . MAO-N has proven particularly amenable to protein engineering, leading to the generation of a panel of synthetically valuable biocatalysts which have recently been commercialized. Here we wish to highlight key synthetic methodologies which have been developed in our laboratory employing these engineered biocatalysts. These include kinetic resolutions (O'Reilly et al., 2014b), deracemizations (Ghislieri et al., 2013b) , oxidative desymmetrizations (Köhler et al., 2010) and asymmetric oxidative Pictet-Spengler reactions (Ghislieri et al., 2013a) , leading to the production of a wide range optically pure alkaloid natural products and active pharmaceutical ingredients.
Telaprevir (12) is an NS3.4A serine protease inhibitor used for the treatment of hepatitis C. The key chiral bicyclic amino acid (13) is a key intermediate for the production of teleprevir which is difficult to access in optically pure form using traditional chemical approaches (Fig. 3) . We devised a biocatalytic approach to this intermediate involving a MAO-N catalyzed desymmetrization (Köhler et al., 2010) . Enantioselective oxidation of prochiral bicyclic amine (14) proceeded with high stereoselectivity using the MAO-N D5 variant to give the key chiral imine (15), which exists in equilibrium with its trimeric form (16). Diastereoselective addition of cyanide and subsequent hydrolysis of the amino-nitrile intermediate (17) with aqueous HCl gave bicyclic amino acid (13) as essentially a single enantiomer and diastereoisomer after a single recrystallization. In parallel, we also devised an alternative synthetic route to telaprevir by subjecting chiral imine (15) to a 3-component Ugi-Passerini reaction .
The deracemization of chiral amines is a highly desirable transformation which, in contrast to kinetic resolution, allows the desired optically pure products to be obtained in 100% theoretical yield. We have developed a chemoenzymatic strategy to achieve this transformation, involving repeated cycles enantioselective oxidation mediated by MAO-N combined with non-selective chemical reduction of the resulting imines (or iminium ions) with BH 3 -NH 3 (Fig. 4) (Alexeeva et al., 2002) . This methodology has been exploited for the deracemization of chiral primary, secondary and tertiary amines, including biologically active natural products and key pharmaceutical intermediates. A recent highlight included the preparative scale deracemizations of 4-chlorobenzhydrylamine (18) and phenyltetrahydroisoquinoline (19) which are important chiral intermediates in the synthesis of the active pharmaceutical ingredients levocetirizine (20) and solifenacin (21), respectively ( Fig. 5) (Ghislieri et al., 2013a) . In these examples we employed our recently evolved MAO-N D11 variant which was specifically engineered for activity towards the sterically demanding benzhydrylamine motif by targeting mutations in the small active site pocket and in the substrate entrance channel (Ghislieri et al., 2013a) . The high levels of selectivity towards (S)-4-chlorobenzhydrylamine are particularly impressive when considering the structural similarity between the two aryl substituents.
In collaboration with the Kroutil group, we recently described a biocatalytic cascade involving MAO-N and the berbererine bridge enzyme (BBE) for the conversion of racemic benzyl substituted isoquinolines to the corresponding optically pure berbines (Schrittwieser et al., 2014) . Reticuline (22) is a key biosynthetic intermediate that lies at the branch point of two important alkaloid biosynthetic pathways, with the (S)-enantiomer involved in berbine biosynthesis and the (R)-enantiomer feeding into the morphine pathway. Heterologously expressed BBE mediated the selective conversion of (S)-reticuline to (S)-scoulerine (23) via an oxidative C-C bond forming process (Fig. 6 ). To overcome the maximum 50% theoretical yield associated with this kinetic resolution, we exploited our MAO-N deracemization methodology. Using the MAO-N D11 variant, racemic reticuline (22) was efficiently converted to the optically pure (S)-enantiomer under standard conditions. By combing these deracemization and kinetic resolution processes into a single operation, the conversion of racemic reticuline to optically pure (S)-scoulerine was achieved in excellent conversion (23). In the final process, a minor adjustment of the chemical reducing agent from NH 3 .BH 3 to morpholine.BH 3 was necessary to minimize deactivation of the BBE.
In a final example, we recently described a novel MAO-N triggered oxidative Pictet-Spengler transformation for the synthesis of the ␤-carboline natural product (R)-harmicine (24) (Fig. 7) (Ghislieri et al., 2013a) . The development of this methodology allowed us to conceive an alternative disconnection strategy to the previously reported synthetic routes. Pyrrolidine (25) is available in one step from tryptamine and butane 1,4-diol using catalytic hydrogen borrowing technology (Cami-Kobeci et al., 2005) . Incubation of this substrate with the MAO-N D9 variant initially resulted in the generation of the iminium ion intermediate (26) which underwent a spontaneous non-selective cyclization to form harmicine as a mixture of enantiomers. Under the reaction conditions, the undesired (S)-enantiomer was converted to the naturally occurring (R)-enantiomer via rounds of MAO-N D9 promoted enantioselective oxidation and non-selective chemical reduction. The conversion of non-chiral pyrrolidine (25) to (R)-harmicine occurs in 99% e.e. with 83% conversion and formally represents a biocatalytic asymmetric oxidative Pictet-Spengler reaction. This two-step synthesis of harmicine from tryptamine represents the shortest synthetic route reported to date, and presents a striking example of how biocatalytic methodology can inspire the development of novel synthetic strategies to access target molecules (Turner and O'Reilly, 2013) .
Conclusion
Biocatalysis is now widely recognized as a competitive and sustainable technology for use in the chemical industry. Today, a growing number of enzyme classes are available with suitable properties for synthetic applications thanks to the collaborative research efforts of scientists across a range of disciplines. Synthetic chemists will continue to exploit these engineered biocatalysts in increasingly inventive ways as they seek to develop efficient synthetic routes to highvalue molecules. In this perspective, we specifically focused upon recent contributions from our laboratory involving the biocatalytic synthesis of high-value chiral amines with -transaminases and monoamine oxidases. Through the examples presented, we wish to highlight how consideration of biocatalytic methodology during retrosynthetic planning can lead to conceptually novel approaches to the construction of high-value molecules (Turner and O'Reilly, 2013) . In the coming years, increasingly sophisticated strategies for directed evolution combined with a fundamental understanding of the determinants of enzyme activity/selectivity at the molecular level will greatly speed up the process of biocatalyst optimization and allow the creation of de novo enzyme activities (Hilvert, 2013) . Such advances will undoubtedly contribute enormously to the widespread implementation of biocatalytic methodology throughout the chemical industry.
